ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Folfox protocol

Also written as “sunitinib + FOLFOX”, “FOLFOX” and “FOLFOX regimen”.

Its studies are mostly in Colorectal Neoplasms · Cholangiocarcinoma · Stomach Neoplasms · Neoplasms, led by 11 companies.

Drug pageFolfox protocol: every studyMany companies study it; this page follows only the 15 they lead. All 89 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Feb 23, 200915 company-led studies, 6 open or runningNext primary completion: Apr 16, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only31 open or runningphase 1since Feb 23, 2009Feb 23, 2009Aug 31, 2030phase 1 · NCT04929223
AstraZeneca21 open or runningphase 3since Nov 13, 2006Nov 13, 2006Nov 30, 2027phase 2 · NCT05702229
Pfizerits history only20 open or runningphase 2since Feb 1, 2008Jan 11, 2008none ahead
Alethia Biotherapeuticsits history only11 open or runningphase 2since Nov 17, 2023Nov 17, 2023none ahead
Amgenits history only10 open or runningphase 2since Mar 20, 2009Mar 20, 2009none ahead
Bristol-Myers Squibbits history only10 open or runningphase 1since May 24, 2007May 24, 2007none ahead
Cardiff Oncologyits history only11 open or runningphase 2since Oct 24, 2023Oct 24, 2023Apr 16, 2027phase 2 · NCT06106308
Fosun Pharmaits history only11 open or runningphase 2since Apr 2, 2025Apr 2, 2025Apr 30, 2028phase 2 · NCT06936527
Genmabits history only11 open or runningphase 2since Apr 4, 2018Apr 4, 2018May 2028phase 2 · NCT03526835
Lisata Therapeuticsits history only10 open or runningphase 2since Jan 26, 2023Jan 26, 2023none ahead

Also a collaborator on its studies: Merck Pte. Ltd., Singapore.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2006First study: phase 3 study in Colorectal NeoplasmsFirst studyNCT00399035 · 1,254 enrolled · Argentina, Australia, Brazil and more
  2. Dec 7, 2022Phase 2 study in Stomach NeoplasmsNCT05702229 · 163 planned · United States, China, Japan and more

Ahead

  1. Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT05702229

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05702229Stomach Neoplasms · United States, China, Japan and more2RecruitingNov 30, 2027163
NCT00399035Colorectal Neoplasms · Argentina, Australia, Brazil and more3CompletedMar 20101,254

How it is read

Names in the registry

  • “sunitinib + FOLFOX”, 7 entries
  • “FOLFOX”, 6 entries
  • “FOLFOX regimen”, 2 entries
  • “FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])”, 2 entries
  • “MCLA-158 + FOLFOX”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.